Aldeyra Therapeutics, Inc.
ALDX
$1.84
$0.010.55%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -19.26% | -21.78% | -3.06% | 6.45% | -10.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -41.34% | -8.99% | 23.84% | 72.82% | 40.48% |
| Operating Income | 41.34% | 8.99% | -23.84% | -72.82% | -40.48% |
| Income Before Tax | 39.40% | 3.58% | -33.67% | -92.27% | -48.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 39.40% | 3.58% | -33.67% | -92.27% | -48.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.40% | 3.58% | -33.67% | -92.27% | -48.77% |
| EBIT | 41.34% | 8.99% | -23.84% | -72.82% | -40.48% |
| EBITDA | 41.52% | 9.03% | -23.99% | -73.37% | -40.76% |
| EPS Basic | 39.94% | 4.26% | -32.72% | -90.67% | -47.24% |
| Normalized Basic EPS | 39.95% | 4.27% | -32.75% | -90.71% | -47.26% |
| EPS Diluted | 39.94% | 4.26% | -32.72% | -90.67% | -47.24% |
| Normalized Diluted EPS | 39.95% | 4.27% | -32.75% | -90.71% | -47.26% |
| Average Basic Shares Outstanding | 0.96% | 0.88% | 0.85% | 0.85% | 0.92% |
| Average Diluted Shares Outstanding | 0.96% | 0.88% | 0.85% | 0.85% | 0.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |